MX2022002418A - Composiciones y metodos de tratamiento de enfermedades vasculares. - Google Patents

Composiciones y metodos de tratamiento de enfermedades vasculares.

Info

Publication number
MX2022002418A
MX2022002418A MX2022002418A MX2022002418A MX2022002418A MX 2022002418 A MX2022002418 A MX 2022002418A MX 2022002418 A MX2022002418 A MX 2022002418A MX 2022002418 A MX2022002418 A MX 2022002418A MX 2022002418 A MX2022002418 A MX 2022002418A
Authority
MX
Mexico
Prior art keywords
methods
compositions
vascular diseases
treating vascular
vpcs
Prior art date
Application number
MX2022002418A
Other languages
English (en)
Inventor
Robert Lanza
Maria Mirotsou
Nutan Prasain
Amrita Singh
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of MX2022002418A publication Critical patent/MX2022002418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Abstract

La presente invención se refiere en general a nuevas células progenitoras vasculares derivadas de mesodermo (meso-VPC) y métodos para producir meso-VPC. La presente invención también se refiere a métodos para tratar una enfermedad vascular, tal como la isquemia crítica de las extremidades, mediante la administración de las meso-VPC a un sujeto.
MX2022002418A 2019-08-28 2020-08-27 Composiciones y metodos de tratamiento de enfermedades vasculares. MX2022002418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962892724P 2019-08-28 2019-08-28
PCT/US2020/048076 WO2021041591A1 (en) 2019-08-28 2020-08-27 Compositions and methods of treating vascular diseases

Publications (1)

Publication Number Publication Date
MX2022002418A true MX2022002418A (es) 2022-03-22

Family

ID=72428364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002418A MX2022002418A (es) 2019-08-28 2020-08-27 Composiciones y metodos de tratamiento de enfermedades vasculares.

Country Status (12)

Country Link
US (1) US20220288131A1 (es)
EP (1) EP4022038A1 (es)
JP (1) JP2022545737A (es)
KR (1) KR20220049618A (es)
CN (1) CN115003794A (es)
AU (1) AU2020337444A1 (es)
BR (1) BR112022003659A2 (es)
CA (1) CA3151636A1 (es)
IL (1) IL290891A (es)
MX (1) MX2022002418A (es)
TW (1) TW202122573A (es)
WO (1) WO2021041591A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
WO2024020399A1 (en) * 2022-07-19 2024-01-25 Lung Biotechnology Pbc Methods for differentiating endothelial cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2426197A1 (en) 2006-04-14 2012-03-07 Advanced Cell Technology, Inc. Hemangio-colony forming cells
KR20110016913A (ko) 2008-05-06 2011-02-18 어드밴스드 셀 테크놀로지, 인코포레이티드 혈관 콜로니 형성 세포 및 비-생착성 혈관 세포
MX349658B (es) * 2011-06-09 2017-08-08 Hoffmann La Roche Metodo para la diferenciacion de las celulas madre pluripotentes en celulas de lecho vascular.
EP2785359B1 (en) 2011-11-30 2018-08-29 Astellas Institute for Regenerative Medicine Mesenchymal stromal cells and uses related thereto
EP3973967A1 (en) 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제

Also Published As

Publication number Publication date
CN115003794A (zh) 2022-09-02
WO2021041591A1 (en) 2021-03-04
BR112022003659A2 (pt) 2022-05-24
JP2022545737A (ja) 2022-10-28
EP4022038A1 (en) 2022-07-06
AU2020337444A1 (en) 2022-03-24
US20220288131A1 (en) 2022-09-15
KR20220049618A (ko) 2022-04-21
TW202122573A (zh) 2021-06-16
CA3151636A1 (en) 2021-03-04
IL290891A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
PH12021551019A1 (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
PH12017501279A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
MX2019007088A (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2020003863A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2022007671A (es) Compuestos antihelminticos que comprenden una estructura de azaindoles.
WO2019212356A8 (en) Tetrazines for high click conjugation yield in vivo and high click release yield
MX2023006744A (es) Compuestos antihelminticos que comprenden una estructura de tienopiridina.
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2022000203A (es) Composiciones de liberacion sostenida de endoxifeno.
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
MX2021011576A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
MX2021011574A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2023001723A (es) Derivados ciclicos de quemerina-9.